ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 6.95M USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 101.95M USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | 238.55M USD | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 488.54M USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $6.95M | $101.95M | (m) | $238.55M | $488.54M | (m) |
| 2026-03-31 | (m) | (m) | $7.95M | $101.47M | (m) | $224.00M | $460.00M | (m) |
| 2025-12-31 | (m) | (m) | $1.00M | $107.96M | (m) | $220.98M | $432.97M | (m) |
| 2025-09-30 | (m) | (m) | $1.00M | $107.50M | (m) | $191.07M | $370.98M | (m) |
| 2025-06-30 | (m) | (m) | $1.00M | $107.05M | (m) | $190.82M | $352.43M | (m) |
| 2025-03-31 | (m) | (m) | (m) | $107.62M | (m) | $198.09M | $344.11M | (m) |
| 2024-12-31 | (m) | (m) | (m) | $107.20M | (m) | $227.96M | $348.89M | (m) |
| 2024-09-30 | (m) | (m) | $99.51M | $105.09M | (m) | $330.56M | $437.35M | (m) |
| 2024-06-30 | (m) | (m) | (m) | $203.81M | (m) | $362.44M | $444.76M | (m) |
| 2024-03-31 | (m) | (m) | (m) | $202.80M | (m) | $403.87M | $478.54M | (m) |
| 2023-12-31 | (m) | (m) | (m) | $201.80M | (m) | $271.86M | $341.37M | (m) |
| 2023-09-30 | (m) | (m) | (m) | $200.78M | (m) | $227.11M | $292.96M | (m) |
| 2023-06-30 | (m) | (m) | (m) | $199.77M | (m) | $268.67M | $320.69M | (m) |
| 2023-03-31 | (m) | (m) | (m) | $198.76M | (m) | $332.40M | $379.46M | (m) |
| 2022-12-31 | (m) | (m) | (m) | $197.77M | (m) | $409.59M | $449.27M | (m) |
| 2022-09-30 | (m) | (m) | (m) | $196.75M | (m) | $476.96M | $508.91M | (m) |
| 2022-06-30 | (m) | (m) | (m) | $73.14M | (m) | $282.17M | $300.46M | (m) |
| 2022-03-31 | (m) | (m) | (m) | $72.74M | (m) | $343.60M | $364.11M | (m) |
| 2021-12-31 | (m) | (m) | (m) | $72.35M | (m) | $387.06M | $408.15M | (m) |
| 2020-12-31 | (m) | (m) | (m) | $0.00 | (m) | $284.44M | $298.27M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |